NexImmune Inc. (NEXI)
OTC PINK OTC PINK Primary Summary
NEXI Stock Alert: NexImmune Delists From Nasdaq
NexImmune (NASDAQ: NEXI ) stock is no longer trading on the Nasdaq Exchange after the company's shares were delisted on Friday morning. This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning.
What Is Going on With NexImmune (NEXI) Stock Today?
Embattled biotechnology firm NexImmune (NASDAQ: NEXI ) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise.
NexImmune Inc. (NEXI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NexImmune Inc. ever had a stock split?
NexImmune Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig R. Jalbert CEO | OTC PINK Exchange | 65344D208 CUSIP |
| US Country | 6 Employees | - Last Dividend | 19 Oct 2023 Last Split | 12 Feb 2021 IPO Date |
Overview
NexImmune, Inc. is a pioneering clinical-stage biotechnology company focused on the creation of innovative therapies that have the potential to cure cancer and other severe immune-mediated diseases. The company leverages its proprietary Artificial Immune Modulation technology, a cutting-edge nanoparticle platform, to develop new approaches to T cell immunotherapies. Since its establishment in 2011, NexImmune has been committed to advancing its research from its headquarters in Gaithersburg, Maryland, aiming to transform the treatment landscape for patients in dire need of effective therapies.
Products and Services
- NEXI-001
An allogeneic cell therapy currently in Phase I/II clinical trials, NEXI-001 is designed for the treatment of patients suffering from acute myeloid leukemia (AML). This product candidate exploits the power of T cells to fight cancer, aiming to offer a new hope for patients battling this aggressive form of leukemia.
- NEXI-002
NEXI-002 is an autologous cell therapy also in Phase I/II clinical trials, targeting patients with relapsed and/or refractory multiple myeloma. Through the customization of T cell therapies to fit the specific needs of the individual's immune system, NEXI-002 seeks to provide a potent therapeutic option for those whose myeloma has proven resistant to other treatments.
- NEXI-003
Currently in the preclinical stage, NEXI-003 is a promising candidate aimed at combating HPV-associated malignancies. Leveraging the company’s novel technology, this therapy embodies NexImmune’s ambition to extend its reach into various cancer types, offering potential treatments for diseases caused by human papillomavirus.
